Microbiota in inflammatory bowel disease pathogenesis and therapy: Is it all about diet?

Nutrition in Clinical Practice

Volumn 30, Issue 6, 2015, Pages 760-779

  Serban, Daniela Elena ^a  

^a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

antibiotics; diet; enteral nutrition; epigenetics; fecal transplantation; genetics; inflammatory bowel disease; microbiome; microbiota; mycobiome; probiotics; virome

Indexed keywords

PREBIOTIC AGENT; PROBIOTIC AGENT; SYNBIOTIC AGENT;

DIET; DIET SUPPLEMENTATION; DISEASE SEVERITY; DYSBIOSIS; ENVIRONMENTAL FACTOR; EPIGENETICS; FECES; GENE INTERACTION; HUMAN; INFLAMMATORY BOWEL DISEASE; METAGENOMICS; MICROFLORA; NONHUMAN; PATHOGENESIS; PROGNOSIS; REVIEW; INFLAMMATORY BOWEL DISEASES; INTESTINE FLORA; MICROBIOLOGY;

GASTROINTESTINAL MICROBIOME; HUMANS; INFLAMMATORY BOWEL DISEASES; PREBIOTICS; PROBIOTICS;

EID: 84946734733     PISSN: 08845336     EISSN: 19412452     Source Type: Journal    
DOI: 10.1177/0884533615606898     Document Type: Review

References (219)

1. Hansen JJ, Sartor RB,. Therapeutic manipulation of the microbiome in IBD: current results and future approaches. Curr Treat Options Gastroenterol. 2015; 13 (1): 105-120.
2. Burisch J, Munkholm P,. The epidemiology of inflammatory bowel disease. Scand J Gastroenterol. 2015; 17: 1-10.
3. Ellinghaus D, Bethune J, Petersen BS, Franke A,. The genetics of Crohn's disease and ulcerative colitis-status quo and beyond. Scand J Gastroenterol. 2015; 50 (1): 13-23.
4. Cosnes J, Gower-Rousseau C, Seksik P, et al. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011; 140: 1785-1794.
5. Ungaro R, Bernstein CN, Gearry R, et al. Antibiotics associated with increased risk of new-onset Crohn's disease but not ulcerative colitis: a meta-analysis. Am J Gastroenterol. 2014; 109 (11): 1728-1738.
6. Joossens M, Simoens M, Vermeire S, et al. Contribution of genetic and environmental factors in the pathogenesis of Crohn's disease in a large family with multiple cases. Inflamm Bowel Dis. 2007; 13: 580-584.
7. Benchimol EI, Mack DR, Guttmann A, et al. Inflammatory bowel disease in immigrants to Canada and their children: a population-based cohort study. Am J Gastroenterol. 2015; 110 (4): 553-563.
8. Orel R, Kamhi Trop T,. Intestinal microbiota, probiotics and prebiotics in inflammatory bowel disease. World J Gastroenterol. 2014; 20 (33): 11505-11524.
9. Serban ED,. Probiotics, prebiotics and synbiotics in inflammatory bowel disease-are they useful? Med Razg. 2009; 48 (suppl 3): 99-113.
10. Serban DE,. The gut microbiota in the metagenomics era: sometimes a friend, sometimes a foe. Roum Arch Microbiol Immunol. 2011; 70 (3): 134-140.
11. Hold GL, Smith M, Grange C, Watt ER, El-Omar EM, Mukhopadhya I,. Role of the gut microbiota in inflammatory bowel disease pathogenesis: what have we learnt in the past 10 years? World J Gastroenterol. 2014; 20 (5): 1192-1210.
12. Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010; 464: 59-65.
13. Human Microbiome Project Consortium. A framework for human microbiome research. Nature. 2012; 486: 215-221.
14. Shreiner AB, Kao JY, Young VB,. The gut microbiome in health and in disease. Curr Opin Gastroenterol. 2015; 31 (1): 69-75.
15. Li J, Jia H, Cai X, et al. An integrated catalog of reference genes in the human gut microbiome. Nat Biotechnol. 2014; 32: 834-841.
16. Quigley EMM,. Intestinal microbiota in health and disease: modern concepts. Gastroenterology. 2015; 148 (4): 853.
17. Sartor RB,. The intestinal microbiota in inflammatory bowel diseases. In: Lewis JD, Ruemmele FM, Wu GD, eds. Nutrition, gut microbiota and immunity: therapeutic targets for IBD. Nestlé Nutr Inst Workshop Ser. 2014; 79: 29-39.
18. Serban DE,. Gastrointestinal cancers: influence of gut microbiota, probiotics and prebiotics. Cancer Lett. 2014; 345: 258-270.
19. Sokol H, Seksik P,. The intestinal microbiota in inflammatory bowel diseases: time to connect with the host. Curr Opin Gastroenterol. 2010; 26: 327-331.
20. Lozupone CA, Stombaugh JI, Gordon JI, et al. Diversity, stability and resilience of the human gut microbiota. Nature. 2012; 489: 220-230.
21. Gevers D, Kugathasan S, Denson LA, et al. The treatment-naive microbiome in new-onset Crohn's disease. Cell Host Microbe. 2014; 15: 382-392.
22. Kostic AD, Xavier RJ, Gevers D,. The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology. 2014; 146 (6): 1489-1499.
23. Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012; 491 (7422): 119-124.
24. Okou DT, Kugathasan S,. Role of genetics in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2014; 20 (10): 1878-1884.
25. Uhlig HH,. Monogenic diseases associated with intestinal inflammation: implications for the understanding of inflammatory bowel disease. Gut. 2013; 62: 1795-1805.
26. Sheehan D, Moran C, Shanahan F,. The microbiota in inflammatory bowel disease. J Gastroenterol. 2015; 50 (5): 495-507.
27. Ventham NT, Kennedy NA, Nimmo ER, Satsangi J,. Beyond gene discovery in inflammatory bowel disease: the emerging role of epigenetics. Gastroenterology. 2013; 45 (2): 293-308.
28. Knights D, Silverberg MS, Weersma RK, et al. Complex host genetics influence the microbiome in inflammatory bowel disease. Genome Med. 2014; 6 (12): 107.
29. Cleynen I, González JR, Figueroa C, et al. Genetic factors conferring an increased susceptibility to develop Crohn's disease also influence disease phenotype: results from the IBDchip European Project. Gut. 2013; 62 (11): 1556-1565.
30. Simpson HL, Campbell BJ, Rhodes JM,. IBD: microbiota manipulation through diet and modified bacteria. Dig Dis. 2014; 32 (suppl 1): 18-25.
31. Ferguson LR,. Nutrigenetics, nutrigenomics and inflammatory bowel diseases. Expert Rev Clin Immunol. 2013; 9 (8): 735-747.
32. Manolakis AC, Kapsoritakis AN, Kapsoritaki A, et al. Readressing the role of Toll-like receptor-4 alleles in inflammatory bowel disease: colitis, smoking, and seroreactivity. Dig Dis Sci. 2013; 58 (2): 371-380.
33. de la Concha EG, Fernandez-Arquero M, Lopez-Nava G, et al. Susceptibility to severe ulcerative colitis is associated with polymorphism in the central MHC gene IKBL. Gastroenterology. 2000; 119: 1491-1495.
34. Tong M, McHardy I, Ruegger P, et al. Reprograming of gut microbiome energy metabolism by the FUT2 Crohn's disease risk polymorphism. ISME J. 2014; 8 (11): 2193-2206.
35. Nimmo ER, Prendergast JG, Aldhous MC,. Genome-wide methylation profiling in Crohn's disease identifies altered epigenetic regulation of key host defense mechanisms including the Th17 pathway. Inflamm Bowel Dis. 2012; 18: 889-899.
36. Cooke J, Zhang H, Greger L,. Mucosal genome-wide methylation changes in inflammatory bowel disease. Inflamm Bowel Dis. 2012; 18: 2128-2137.
37. Adams AT, Kennedy NA, Hansen R, et al. Two-stage genome-wide methylation profiling in childhood-onset Crohn's disease implicates epigenetic alterations at the VMP1/MIR21 and HLA loci. Inflamm Bowel Dis. 2014; 20 (10): 1784-1793.
38. Chen WX, Ren LH, Shi RH,. Implication of miRNAs for inflammatory bowel disease treatment: systematic review. World J Gastrointest Pathophysiol. 2014; 5 (2): 63-70.
39. Brest P, Lapaquette P, Souidi M,. A synonymous variant in IRGM alters a binding site for miR-196 and causes deregulation of IRGM-dependent xenophagy in Crohn's disease. Nat Genet. 2011; 43: 242-245.
40. Nguyen HT, Dalmasso G, Müller S, Carrière J, Seibold F, Darfeuille-Michaud A,. Crohn's disease-associated adherent invasive Escherichia coli modulate levels of microRNAs in intestinal epithelial cells to reduce autophagy. Gastroenterology. 2014; 146: 508-519.
41. Ruemmele FM, Pigneur B, Garnier-Lengliné H,. Enteral nutrition as treatment option for Crohn's disease: in kids only? In: Lewis JD, Ruemmele FM, Wu GD, eds. Nutrition, gut microbiota and immunity: therapeutic targets for IBD. Nestlé Nutr Inst Workshop Ser. 2014; 79: 115-123.
42. Haberman Y, Tickle TL, Dexheimer PJ, et al. Pediatric Crohn disease patients exhibit specific ileal transcriptome and microbiome signature. J Clin Invest. 2014; 124 (8): 3617-3633.
43. Levine A, Wine E,. Effects of enteral nutrition on Crohn disease: clues to the impact of diet on disease pathogenesis. Inflamm Bowel Dis. 2013; 19: 1322-1329.
44. De Cruz P, Prideaux L, Wagner J, et al. Characterization of the gastrointestinal microbiota in health and inflammatory bowel disease. Inflamm Bowel Dis. 2012; 18 (2): 372-390.
45. Morgan XC, Tickle TL, Sokol H, et al. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol. 2012; 13 (9): R79.
46. Sepehri S, Kotlowski R, Bernstein CN, Krause DO,. Microbial diversity of inflamed and noninflamed gut biopsy tissues in inflammatory bowel disease. Inflamm Bowel Dis. 2007; 13: 675-683.
47. Walker AW, Sanderson JD, Churcher C, et al. High-throughput clone library analysis of the mucosa-associated microbiota reveals dysbiosis and differences between inflamed and non-inflamed regions of the intestine in inflammatory bowel disease. BMC Microbiol. 2011; 11: 7.
48. Hall LJ, Walshaw J, Watson AJ,. Gut microbiome in new onset Crohn's disease. Gastroenterology. 2014; 147 (4): 932-934.
49. Leake I,. IBD. Specific genetic and microbial signature associated with paediatric ileal Crohn's disease. Nat Rev Gastroenterol Hepatol. 2014; 11 (9): 515.
50. Conte MP, Schippa S, Zamboni I, et al. Gut-associated bacterial microbiota in paediatric patients with inflammatory bowel disease. Gut. 2006; 55 (12): 1760-1767.
51. Hansen R, Reiff C, Russell RK, et al. Colonic mucosal bacterial diversity of de-novo extensive paediatric ulcerative colitis by next-generation sequencing. Gut. 2011; 60: A146-A147.
52. Zhang L, Man SM, Day AS, et al. Detection and isolation of Campylobacter species other than C. jejuni from children with Crohn's disease. J Clin Microbiol. 2009; 47 (2): 453-455.
53. Hansen R, Berry SH, Mukhopadhya I, et al. The microaerophilic microbiota of de-novo paediatric inflammatory bowel disease: the BISCUIT study. PLoS One. 2013; 8: e58825.
54. Hansen R, Russell RK, Reiff C, et al. Microbiota of de-novo pediatric IBD: increased Faecalibacterium prausnitzii and reduced bacterial diversity in Crohn's but not in ulcerative colitis. Am J Gastroenterol. 2012; 107: 1913-1922.
55. Kellermayer R, Mir SA, Nagy-Szakal D, et al. Microbiota separation and C-reactive protein elevation in treatment naïve pediatric granulomatous Crohn disease. J Pediatr Gastroenterol Nutr. 2012; 55: 243-250.
56. Kolho KL, Korpela K, Jaakkola T, et al. Fecal microbiota in pediatric inflammatory bowel disease and its relation to inflammation. Am J Gastroenterol. 2015; 110 (6): 921-930.
57. Kaakoush NO, Day AS, Huinao KD, et al. Microbial dysbiosis in pediatric patients with Crohn's disease. J Clin Microbiol. 2012; 50: 3258-3266.
58. Man SM, Zhang L, Day AS, Leach ST, Lemberg DA, Mitchell H,. Campylobacter concisus and other Campylobacter species in children with newly diagnosed Crohn's disease. Inflamm Bowel Dis. 2010; 16: 1008-1016.
59. Papa E, Docktor M, Smillie C, et al. Non-invasive mapping of the gastrointestinal microbiota identifies children with inflammatory bowel disease. PLoS One. 2012; 7 (6): e39242.
60. Fyderek K, Strus M, Kowalska-Duplaga K, et al. Mucosal bacterial microflora and mucus layer thickness in adolescents with inflammatory bowel disease. World J Gastroenterol. 2009; 15: 5287-5294.
61. Frank DN, St Amand AL, Feldman RA, et al. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci USA. 2007; 104: 13780-13785.
62. Sokol H, Pigneur B, Watterlot L, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci USA. 2008; 105: 16731-16736.
63. Willing B, Halfvarson J, Dicksved J, et al. Twin studies reveal specific imbalances in the mucosa-associated microbiota of patients with ileal Crohn's disease. Inflamm Bowel Dis. 2009; 15 (5): 653-660.
64. Sokol H, Seksik P, Furet JP, et al. Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflamm Bowel Dis. 2009; 15: 1183-1189.
65. Joossens M, Huys G, Cnockaert M, et al. Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives. Gut. 2011; 60: 631-637.
66. Hedin C, van der Gast CJ, Rogers GB, et al. Siblings of patients with Crohn's disease exhibit a biologically relevant dysbiosis in mucosal microbial metacommunities [published online April 8, 2015]. Gut.
67. Sokol H, Seksik P, Rigottier-Gois L, et al. Specificities of the fecal microbiota in inflammatory bowel disease. Inflamm Bowel Dis. 2006; 12 (2): 106-111.
68. Swidsinski A, Loening-Baucke V, Vaneechoutte M, et al. Active Crohn's disease and ulcerative colitis can be specifically diagnosed and monitored based on the biostructure of the fecal flora. Inflamm Bowel Dis. 2008; 14: 147-161.
69. Furusawa Y, Obata Y, Fukuda S, et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature. 2013; 504: 446-450.
70. Atarashi K, Tanoue T, Oshima K, et al. Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. Nature. 2013; 500: 232-236.
71. Round JL, Mazmanian SK,. Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota. Proc Natl Acad Sci USA. 2010; 107: 12204-12209.
72. Quévrain E, Maubert MA, Michon C, et al. Identification of an anti-inflammatory protein from Faecalibacterium prausnitzii, a commensal bacterium deficient in Crohn's disease. [published online June 4, 2015]. Gut.
73. Andoh A, Kuzuoka H, Tsujikawa T, et al. Multicenter analysis of fecal microbiota profiles in Japanese patients with Crohn's disease. J Gastroenterol. 2012; 47 (12): 1298-1307.
74. Dicksved J, Halfvarson J, Rosenquist M, et al. Molecular analysis of the gut microbiota of identical twins with Crohn's disease. ISME J. 2008; 2: 716-727.
75. Vaishampayan PA, Kuehl JV, Froula JL, Morgan JL, Ochman H, Francino MP,. Comparative metagenomics and population dynamics of the gut microbiota in mother and infant. Genome Biol Evol. 2010; 2: 53-66.
76. Frank DN, Robertson CE, Hamm CM, et al. Disease phenotype and genotype are associated with shifts in intestinal-associated microbiota in inflammatory bowel diseases. Inflamm Bowel Dis. 2011; 17: 179-184.
77. Darfeuille-Michaud A, Boudeau J, Bulois P, et al. High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology. 2004; 127: 412-421.
78. Martinez-Medina M, Aldeguer X, Lopez-Siles M, et al. Molecular diversity of Escherichia coli in the human gut: new ecological evidence supporting the role of adherent-invasive E. coli (AIEC) in Crohn's disease. Inflamm Bowel Dis. 2009; 15: 872-882.
79. Negroni A, Costanzo M, Vitali R, et al. Characterization of adherent-invasive Escherichia coli isolated from pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis. 2012; 18: 913-924.
80. Sepheri S, Khafipour E, Bernstein CN, et al. Characterization of Escherichia coli isolated from gut biopsies of newly diagnosed patients with inflammatory bowel disease. Inflamm Bowel Dis. 2011; 17 (7): 1451-1463.
81. Rahman K, Sasaki M, Nusrat A, Klapproth JM,. Crohn's disease-associated Escherichia coli survive in macrophages by suppressing NFκB signaling. Inflamm Bowel Dis. 2014; 20 (8): 1419-1425.
82. Carvalho FA, Barnich N, Sivignon A, et al. Crohn's disease adherent-invasive Escherichia coli colonize and induce strong gut inflammation in transgenic mice expressing human CEACAM. J Exp Med. 2009; 206 (10): 2179-2189.
83. Bücker R, Schulz E, Günzel D, et al. α-Haemolysin of Escherichia coli in IBD: a potentiator of inflammatory activity in the colon. Gut. 2014; 63 (12): 1893-1901.
84. Bringer MA, Billard E, Glasser AL, Colombel JF, Darfeuille-Michaud A,. Replication of Crohn's disease-associated AIEC within macrophages is dependent on TNF-α secretion. Lab Invest. 2012; 92: 411-419.
85. Elliott TR, Hudspith BN, Rayment NB, et al. Defective macrophage handling of Escherichia coli in Crohn's disease. J Gastroenterol Hepatol. 2015; 30 (8): 1265-1274.
86. Mahendran V, Riordan SM, Grimm MC, et al. Prevalence of Campylobacter species in adult Crohn's disease and the preferential colonization sites of Campylobacter species in the human intestine. PLoS One. 2011; 6: e25417.
87. Mukhopadhya I, Thomson JM, Hansen R, Berry SH, ElOmar EM, Hold GL,. Detection of Campylobacter concisus and other Campylobacter species in colonic biopsies from adults with ulcerative colitis. PLoS One. 2011; 6: e21490.
88. Zhang L, Lee H, Grimm MC, Riordan SM, Day AS, Lemberg DA,. Campylobacter concisus and inflammatory bowel disease. World J Gastroenterol. 2014; 20 (5): 1259-1267.
89. Man SM, Kaakoush NO, Leach ST, et al. Host attachment, invasion, and stimulation of proinflammatory cytokines by Campylobacter concisus and other non- Campylobacter jejuni Campylobacter species. J Infect Dis. 2010; 202: 1855-1865.
90. Rigottier-Gois L,. Dysbiosis in inflammatory bowel diseases: the oxygen hypothesis. ISME J. 2013; 7: 1256-1261.
91. Lepage P, Mondot S, Vasquez N, et al. Bacterial recolonization after gut resection for Crohn's disease: uniformity as an essential factor toward remission. Gut. 2009; 58 (suppl II): OPO20.
92. De Cruz P, Kang S, Wagner J, et al. Association between specific mucosa-associated microbiota in Crohn's disease at the time of resection and subsequent disease recurrence: a pilot study. J Gastroenterol Hepatol. 2015; 30 (2): 268-278.
93. Batista D, Raffals L,. Role of intestinal bacteria in the pathogenesis of pouchitis. Inflamm Bowel Dis. 2014; 20 (8): 1481-1486.
94. Komanduri S, Gillevet PM, Sikaroodi M, et al. Dysbiosis in pouchitis: evidence of unique microfloral patterns in pouch inflammation. Clin Gastroenterol Hepatol. 2007; 5: 352-360.
95. Zella GC, Hait EJ, Glavan T, et al. Distinct microbiome in pouchitis compared to healthy pouches in ulcerative colitis and familial adenomatous polyposis. Inflamm Bowel Dis. 2010; 17 (5): 1092-1100.
96. Tyler AD, Knox N, Kabakchiev B, et al. Characterization of the gut-associated microbiome in inflammatory pouch complications following ileal pouch-anal anastomosis. PLoS One. 2013; 8 (9): e66934.
97. Rajca S, Grondin V, Louis E, et al. Alterations in the intestinal microbiome (dysbiosis) as a predictor of relapse after infliximab withdrawal in Crohn's disease. Inflamm Bowel Dis. 2014; 20 (6): 978-986.
98. Ohkusa T, Sato N, Ogihara T, et al. Fusobacterium varium localized in the colonic mucosa of patients with ulcerative colitis stimulates species-specific antibody. J Gastroenterol Hepatol. 2002; 17: 849-853.
99. Strauss J, Kaplan GG, Beck Pl, et al. Invasive potential of gut mucosa-derived Fusobacterium nucleatum positively correlates with IBD status of the host. Inflamm Bowel Dis. 2011; 17: 1971-1978.
100. Lennon G, Balfe Á Bambury N, et al. Correlations between colonic crypt mucin chemotype, inflammatory grade and Desulfovibrio species in ulcerative colitis. Colorectal Dis. 2014; 16 (5): O161-O169.
101. Rashid T, Ebringer A, Wilson C,. The role of Klebsiella in Crohn's disease with a potential for the use of antimicrobial measures. Int J Rheumatol. 2013; 2013: 610393.
102. Thomson JM, Hansen R, Berry SH, et al. Enterohepatic helicobacter in ulcerative colitis: potential pathogenic entities? PLoS One. 2011; 6: e17184.
103. Kellermayer R,. Burdening questions about Clostridium difficile in pediatric inflammatory bowel diseases. J Pediatr Gastroenterol Nutr. 2015; 60 (4): 421-422.
104. Mir SA, Kellermayer R,. Clostridium difficile infection in newly diagnosed pediatric inflammatory bowel disease in the mid-Southern United States. J Pediatr Gastroenterol Nutr. 2013; 57: 487-488.
105. Martinelli M, Strisciuglio C, Veres G, et al. Clostridium difficile and pediatric inflammatory bowel disease: a prospective, comparative, multicenter, ESPGHAN study. Inflamm Bowel Dis. 2014; 20 (12): 2219-2225.
106. Sager K, Alam S, Bond A, Chinnappan L, Probert CS,. Review article: cytomegalovirus and inflammatory bowel disease. Aliment Pharmacol Ther. 2015; 41 (8): 725-733.
107. Machiels K, Joossens M, Sabino J, et al. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut. 2014; 63 (8): 1275-1283.
108. Erickson AR, Cantarel BL, Lamendella R, et al. Integrated metagenomics/metaproteomics reveals human host-microbiota signatures of Crohn's disease. PLoS One. 2012; 7: e49138.
109. Marchesi JR, Holmes E, Khan F, et al. Rapid and noninvasive metabonomic characterization of inflammatory bowel disease. J Proteome Res. 2007; 6: 546-551.
110. Davenport M, Poles J, Leung JM, et al. Metabolic alterations to the mucosal microbiota in inflammatory bowel disease. Inflamm Bowel Dis. 2014; 20 (4): 723-731.
111. James SL, Christophersen CT, Bird AR, et al. Abnormal fibre usage in UC in remission. Gut. 2015; 64: 562-570.
112. Jansson J, Willing B, Lucio M, et al. Metabolomics reveals metabolic biomarkers of Crohn's disease. PLoS One. 2009; 4: e6386.
113. Balasubramanian K, Kumar S, Singh RR, et al. Metabolism of the colonic mucosa in patients with inflammatory bowel diseases: an in vitro proton magnetic resonance spectroscopy study. Magn Reson Imaging. 2009; 27: 79-86.
114. Bjerrum JT, Nielsen OH, Hao F, et al. Metabonomics in ulcerative colitis: diagnostics, biomarker identification, and insight into the pathophysiology. J Proteome Res. 2010; 9: 954-962.
115. Sharma U, Singh RR, Ahuja V, et al. Similarity in the metabolic profile in macroscopically involved and un-involved colonic mucosa in patients with inflammatory bowel disease: an in vitro proton ((1)H) MR spectroscopy study. Magn Reson Imaging. 2010; 28: 1022-1029.
116. Meelu P, Marin R, Clish C, et al. Impaired innate immune function associated with fecal supernatant from Crohn's disease patients: insights into potential pathogenic role of the microbiome. Inflamm Bowel Dis. 2014; 20 (7): 1139-1146.
117. Wagner J, Maksimovic J, Farries G, et al. Bacteriophages in gut samples from pediatric Crohn's disease patients: metagenomic analysis using 454 pyrosequencing. Inflamm Bowel Dis. 2013; 19: 1598-1608.
118. Lepage P, Colombet J, Marteau P, et al. Dysbiosis in inflammatory bowel disease: a role for bacteriophages? Gut. 2008; 57: 424-425.
119. Perez-Brocal V, Garcia-Lopez R, Vazquez-Castellanos JF, et al. Study of the viral and microbial communities associated with Crohn's disease: a metagenomic approach. Clin Transl Gastroenterol. 2013; 4: e36.
120. Norman JM, Handley SA, Baldridge MT, et al. Disease-specific alterations in the enteric virome in inflammatory bowel disease. Cell. 2015; 60 (3): 447-460.
121. Chamaillard M, Cesaro A, Lober PE, Hober D,. Decoding norovirus infection in Crohn's disease. Inflamm Bowel Dis. 2014; 20 (4): 767-770.
122. Wang W, Jovel J, Halloran B, et al. Metagenomic analysis of microbiome in colon tissue from subjects with inflammatory bowel diseases reveals interplay of viruses and bacteria. Inflamm Bowel Dis. 2015; 21 (6): 1419-1427.
123. Ott SJ, Kuhbacher T, Musfeldt M, et al. Fungi and inflammatory bowel diseases: alterations of composition and diversity. Scand J Gastroenterol. 2008; 43 (7): 831-841.
124. Li Q, Wang C, Tang C, He Q, Li N, Li J,. Dysbiosis of gut fungal microbiota is associated with mucosal inflammation in Crohn's disease. J Clin Gastroenterol. 2014; 48 (6): 513-523.
125. Mukhopadhya I, Hansen R, Meharg C, et al. The fungal microbiota of de-novo paediatric inflammatory bowel disease. Microbes Infect. 2015; 17 (4): 304-310.
126. Chehoud C, Albenberg LG, Judge C, et al. Fungal signature in the gut microbiota of pediatric patients with inflammatory bowel disease [published online June 16, 2015]. Inflamm Bowel Dis.
127. Li F, Liu X, Wang W, Zhang D,. Consumption of vegetables and fruit and the risk of inflammatory bowel disease: a meta-analysis. Eur J Gastroenterol Hepatol. 2015; 27 (6): 623-630.
128. Arpaia N, Campbell C, Fan X, et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature. 2013; 504 (7480): 451-455.
129. Singh N, Gurav A, Sivaprakasam S, et al. Activation of GPR 109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis. Immunity. 2014; 40 (1): 128-139.
130. Dixon LJ, Kabi A, Nickerson KP, McDonald C,. Combinatorial effects of diet and genetics on inflammatory bowel disease pathogenesis. Inflamm Bowel Dis. 2015; 21 (4): 912-922.
131. Pfeffer-Gik T, Levine A,. Dietary clues to the pathogenesis of Crohn's disease. Dig Dis. 2014; 32 (4): 389-394.
132. Sigall-Boneh R, Pfeffer-Gik T, Segal I, Zangen T, Boaz M, Levine A,. Partial enteral nutrition with a Crohn's disease exclusion diet is effective for induction of remission in children and young adults with Crohn's disease. Inflamm Bowel Dis. 2014; 20: 1353-1360.
133. Chassaing B, Koren O, Goodrich JK, et al. Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome. Nature. 2015; 519 (7541): 92-96.
134. Roberts C, Keita A, Duncan S, et al. Translocation of Crohn's disease Escherichia coli across M-cells contrasting effects of soluble plantfibers and emulsifier. Gut. 2010; 59: 1331-1339.
135. Swidsinski A, Ung V, Sydora B, et al. Bacterial overgrowth and inflammation of small intestine after carboxymethylcellulose ingestion in genetically susceptible mice. Inflamm Bowel Dis. 2009; 15: 359-364.
136. Nickerson KP, Chanin R, McDonald C,. Deregulation of intestinal anti-microbial defense by the dietary additive, maltodextrin. Gut Microbes. 2015; 6 (1): 78-83.
137. Martinez-Medina M, Denizot J, Dreux N, et al. Western diet induces dysbiosis with increased E coli in CEABAC10 mice, alters host barrier function favouring AIEC colonisation. Gut. 2014; 63 (1): 116-124.
138. Martin TD, Chan SS, Hart AR,. Environmental factors in the relapse and recurrence of inflammatory bowel disease: a review of the literature. Dig Dis Sci. 2015; 60 (5): 1396-1405.
139. Matsuura M, Liu B, Carroll I, et al. Selective alteration of growth and virulence for iron-dependent bacterial species: possible novel mechanisms of detrimental effects of dietary iron on intestinal inflammation. Gastroenterology. 2010; 138: S-580.
140. Mouli VP, Ananthakrishnan AN,. Review article: vitamin D and inflammatory bowel diseases. Aliment Pharmacol Ther. 2014; 39: 125-136.
141. Wu GD, Chen J, Hoffmann C, et al. Linking long-term dietary patterns with gut microbial enterotypes. Science. 2011; 334: 105-108.
142. Bibiloni R, Tandon P, Vargas-Voracka F, et al. Differential clustering of bowel biopsy-associated bacterial profiles of specimens collected in Mexico and Canada: what do these profiles represent? J Med Microbiol. 2008; 57 (pt 1): 111-117.
143. Ghouri YA, Richards DM, Rahimi EF, Krill JT, Jelinek KA, DuPont AW,. Systematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel disease. Clin Exp Gastroenterol. 2014; 7: 473-487.
144. Ruemmele FM, Veres G, Kolho KL, et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. J Crohns Colitis. 2014; 8 (10): 1179-1207.
145. Wall CL, Day AS, Gearry RB,. Use of exclusive enteral nutrition in adults with Crohn's disease: a review. World J Gastroenterol. 2013; 19: 7652-7660.
146. Bernstein CN,. Treatment of IBD: where we are and where we are going. Am J Gastroenterol. 2015; 110 (1): 114-126.
147. Pigneur B, Lepage P, Schmitz J, et al. Effect of exclusive enteral nutrition on the course of Crohn's disease and intestinal microbiota. J Pediatr Gastroenterol Nutr. 2013; 56 (suppl 2):PA-G-0046.
148. Tjellström B, Högberg L, Stenhammar L, et al. Effect of exclusive enteral nutrition on gut microflora function in children with Crohn's disease. Scand J Gastroenterol. 2012; 47: 154-159.
149. Gerasimidis K, Bertz M, Hanske L, et al. Decline in presumptively protective gut bacterial species and metabolites are paradoxically associated with disease improvement in pediatric Crohn's disease during enteral nutrition. Inflamm Bowel Dis. 2014; 20 (5): 861-871.
150. Kaakoush NO, Day AS, Leach ST, Lemberg DA, Nielsen S, Mitchell HM,. Effect of exclusive enteral nutrition on the microbiota of children with newly diagnosed Crohn's disease. Clin Transl Gastroenterol. 2015; 6: e71.
151. Herfarth HH, Martin CF, Sandler RS, Kappelman MD, Long MD,. Prevalence of a gluten-free diet and improvement of clinical symptoms in patients with inflammatory bowel diseases. Inflamm Bowel Dis. 2014; 20 (7): 1194-1197.
152. Jorgensen SP, Agnholt J, Glerup H, et al. Clinical trial: vitamin D3 treatment in Crohn's disease-a randomized double-blind placebo-controlled study. Aliment Pharmacol Ther. 2010; 32: 377-383.
153. Raftery T, Martineau AR, Greiller CL, et al. Effects of vitamin D supplementation on intestinal permeability, cathelicidin and disease markers in Crohn's disease: results from a randomised double-blind placebo-controlled study. United Eur Gastroenterol J. 2015; 3 (3): 294-302.
154. Lee D, Albenberg L, Compher C, et al. Diet in the pathogenesis and treatment of inflammatory bowel diseases. Gastroenterology. 2015; 148 (6): 1087-1106.
155. Bernstein CN,. Antibiotics, probiotics and prebiotics in IBD. Nestle Nutr Inst Workshop Ser. 2014; 79: 83-100.
156. Sokol H,. Probiotics and antibiotics in IBD. Dig Dis. 2014; 32 (suppl 1): 10-17.
157. Hill C, Guarner F, Reid G, et al. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014; 11: 506-514.
158. Jonkers D, Penders J, Masclee A, Pierik M,. Probiotics in the management of inflammatory bowel disease: a systematic review of intervention studies in adult patients. Drugs. 2012; 72 (6): 803-823.
159. Shen J, Zuo ZX, Mao AP,. Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis, Crohn's disease, and pouchitis: Meta-analysis of randomized controlled trials. Inflamm Bowel Dis. 2014; 20 (1): 21-35.
160. Petersen AM, Mirsepasi H, Halkjær SI, Mortensen EM, Nordgaard-Lassen I, Krogfelt KA,. Ciprofloxacin and probiotic Escherichia coli Nissle add-on treatment in active ulcerative colitis: a double-blind randomized placebo controlled clinical trial. J Crohns Colitis. 2014; 8 (11): 1498-1505.
161. Oliva S, Di Nardo G, Ferrari F, et al. Randomised clinical trial: the effectiveness of Lactobacillus reuteri ATCC 55730 rectal enema in children with active distal ulcerative colitis. Aliment Pharmacol Ther. 2012; 35 (3): 327-334.
162. Mardini HE, Grigorian AY,. Probiotic mix VSL#3 is effective adjunctive therapy for mild to moderately active ulcerative colitis: a meta-analysis. Inflamm Bowel Dis. 2014; 20 (9): 1562-1567.
163. Floch MH,. Recommendations for probiotic use in humans-a 2014 update. Pharmaceuticals. 2014; 7: 999-1007.
164. Gionchetti P, Calafiore A, Riso D, et al. The role of antibiotics and probiotics in pouchitis. Ann Gastroenterol. 2012; 25 (2): 100-105.
165. Guslandi M,. Role of probiotics in the management of pouchitis. Curr Pharm Des. 2014; 20 (28): 4561-4564.
166. Gionchetti P, Rizzello F, Morselli C, et al. High-dose probiotics for the treatment of active pouchitis. Dis Colon Rectum. 2007; 50 (12): 2075-2082.
167. Laake KO, Bjorneklett A, Aamodt G, et al. Outcome of four weeks' intervention with probiotics on symptoms and endoscopic appearance after surgical reconstruction with a J-configurated ileal-pouch-anal-anastomosis in ulcerative colitis. Scand J Gastroenterol. 2005; 40 (1): 43-51.
168. Holubar SD, Cima RR, Sandborn WJ, Pardi DS,. Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. Cochrane Database Syst Rev. 2010;(6):CD001176.
169. Roberfroid M, Gibson GR, Hoyles L, et al. Prebiotic effects: metabolic and health benefits. Br J Nutr. 2010; 104 (suppl 2): S1-S63.
170. Mitsuyama K, Saiki T, Kanauchi O, et al. Treatment of ulcerative colitis with germinated barley foodstuff feeding: a pilot study. Aliment Pharmacol Ther. 1998; 12 (12): 1225-1230.
171. Kanauchi O, Suga T, Tochihara M, et al. Treatment of ulcerative colitis by feeding with germinated barley foodstuff: first report of a multicenter open control trial. J Gastroenterol. 2002; 37 (suppl 14): 67-72.
172. Kanauchi O, Mitsuyama K, Homma T, et al. Treatment of ulcerative colitis patients by long-term administration of germinated barley foodstuff: multi-center open trial. Int J Mol Med. 2003; 12 (5): 701-704.
173. Suzuki A, Mitsuyama K, Koga H, et al. Bifidogenic growth stimulator for the treatment of active ulcerative colitis: a pilot study. Nutrition. 2006; 22: 76-81.
174. Casellas F, Borruel N, Torrejon A, et al. Oral oligofructose-enriched inulin supplementation in acute ulcerative colitis is well tolerated and associated with lowered faecal calprotectin. Aliment Pharmacol Ther. 2007; 25 (9): 1061-1067.
175. Hanai H, Kanauchi O, Mitsuyama K, et al. Germinated barley foodstuff prolongs remission in patients with ulcerative colitis. Int J Mol Med. 2004; 13 (5): 643-647.
176. Fernández-Bañares F, Hinojosa J, Sánchez-Lombraña JL, et al. Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. Spanish Group for the Study of Crohn's Disease and Ulcerative Colitis (GETECCU). Am J Gastroenterol. 1999; 94: 427-433.
177. Welters CF, Heineman E, Thunnissen FB, van den Bogaard AE, Soeters PB, Baeten CG,. Effect of dietary inulin supplementation on inflammation of pouch mucosa in patients with an ileal pouch-anal anastomosis. Dis Colon Rectum. 2002; 45 (5): 621-627.
178. Lindsay JO, Whelan K, Stagg AJ, et al. Clinical, microbiological, and immunological effects of fructo-oligosaccharide in patients with Crohn's disease. Gut. 2006; 55: 348-355.
179. Benjamin JL, Hedin CRH, Koutsoumpas A, et al. Randomized, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn's disease. Gut. 2011; 60: 923-929.
180. De Preter V, Joossens M, Ballet V, et al. Metabolic profiling of the impact of oligofructose-enriched inulin in Crohn's disease patients: a double-blind randomized controlled trial. Clin Transl Gastroenterol. 2013; 4: e30.
181. Joossens M, De Preter V, Ballet V, Verbeke K, Rutgeerts P, Vermeire S,. Effect of oligofructose-enriched inulin (OF-IN) on bacterial composition and disease activity of patients with Crohn's disease: results from a double-blinded randomised controlled trial. Gut. 2012; 61 (6): 958.
182. Furrie E, Macfarlane S, Kennedy A, et al. Synbiotic therapy (Bifidobacterium longum /Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. Gut. 2005; 54: 242-249.
183. Fujimori S, Gudis K, Mitsui K, et al. A randomized controlled trial on the efficacy of synbiotic versus probiotic or prebiotic treatment to improve the quality of life in patients with ulcerative colitis. Nutrition. 2009; 25 (5): 520-525.
184. Ishikawa H, Matsumoto S, Ohashi Y, et al. Beneficial effects of probiotic Bifidobacterium and galacto-oligosaccharide in patients with ulcerative colitis: a randomized controlled study. Digestion. 2011; 84: 128-133.
185. Guslandi M,. Efficacy of a symbiotic product during clinical relapse of ulcerative colitis. J Clin Gastroenterol. 2011; 45 (5): 475-476.
186. Friedman G, George J,. Treatment of refractory "pouchitis" with prebiotic and probiotic therapy. Gastroenterology. 2000; 118: A778.
187. Fujimori S, Tatsuguchi A, Gudis K, et al. High dose probiotic and prebiotic cotherapy for remission induction of active Crohn's disease. J Gastroenterol Hepatol. 2007; 22 (8): 1199-1204.
188. Steed H, Macfarlane GT, Blackett KL, et al. Clinical trial: the microbiological and immunological effects of synbiotic consumption-a randomized double-blind placebo-controlled study in active Crohn's disease. Aliment Pharmacol Ther. 2010; 32: 872-883.
189. Hansen R, Mahdi G, McIntyre K, Macfarlane GT, Macfarlane S, Wilson DC,. Synbiotics for inflammatory bowel disease: useful in adults but problematic in paediatrics. Arch Dis Child. 2011; 96 (1): A18-A19.
190. Hedin CR, Mullard M, Sharratt E, et al. Probiotic and prebiotic use in patients with inflammatory bowel disease: a case-control study. Inflamm Bowel Dis. 2010; 16 (12): 2099-2108.
191. Khan KJ, Ullman TA, Ford AC, et al. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol. 2011; 106: 661-673.
192. Wang SL, Wang ZR, Yang CQ,. Meta-analysis of broad-spectrum antibiotic therapy in patients with active inflammatory bowel disease. Exp Ther Med. 2012; 4: 1051-1056.
193. Su JW, Ma JJ, Zhang HJ,. Use of antibiotics in patients with Crohn's disease: a systematic review and meta-analysis. J Dig Dis. 2015; 16 (2): 58-66.
194. Levine A, Turner D,. Combined azithromycin and metronidazole therapy is effective in inducing remission in pediatric Crohn's disease. J Crohns Colitis. 2011; 5 (3): 222-226.
195. Dewint P, Hansen BE, Verhey E, et al. Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI). Gut. 2014; 63 (2): 292-299.
196. Ohkusa T, Kato K, Terao S, et al. Newly developed antibiotic combination therapy for ulcerative colitis: a double-blind placebo-controlled multicenter trial. Am J Gastroenterol. 2010; 105 (8): 1820-1829.
197. Turner D, Levine A, Kolho KL, Shaoul R, Ledder O,. Combination of oral antibiotics may be effective in severe pediatric ulcerative colitis: a preliminary report. J Crohns Colitis. 2014; 8 (11): 1464-1470.
198. Anderson JL, Edney RJ, Whelan K,. Systematic review: faecal microbiota transplantation in the management of inflammatory bowel disease. Aliment Pharmacol Ther. 2012; 36: 503-516.
199. Kump PK, Grochenig HP, Lackner S, et al. Alteration of intestinal dysbiosis by fecal microbiota transplantation does not induce remission in patients with chronic active ulcerative colitis. Inflamm Bowel Dis. 2013; 19: 2155-2165.
200. Colman RJ, Rubin DT,. Fecal microbiota transplantation as therapy for inflammatory bowel disease: a systematic review and meta-analysis. J Crohns Colitis. 2014; 8 (12): 1569-1581.
201. Moayyedi P, Surette M, Wolfe M, et al. A randomized, placebo controlled trial of fecal microbiota therapy in active ulcerative colitis. Gastroenterology. 2014; 146: S-159.
202. Moayyedi P, Surette MG, Kim PT, et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology. 2015; 149 (1): 102-109.e6.
203. Rossen NG, Fuentes S, van der Spek MJ, et al. Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. Gastroenterology. 2015; 149 (1): 110-118.e4.
204. Grinspan AM, Kelly CP,. Fecal microbiota transplantation for ulcerative colitis: not just yet. Gastroenterology. 2015; 149 (1): 15-18.
205. Vrieze A, de Groot PF, Kootte RS, Knaapen M, van Nood E, Nieuwdorp M,. Fecal transplant: a safe and sustainable clinical therapy for restoring intestinal microbial balance in human disease? Best Pract Res Clin Gastroenterol. 2013; 27: 127-137.
206. Garg SK, Croft AM, Bager P,. Helminth therapy (worms) for induction of remission in inflammatory bowel disease. Cochrane Database Syst Rev. 2014; 1:CD009400.
207. Merga Y, Campbell BJ, Rhodes JM,. Mucosal barrier, bacteria and inflammatory bowel disease: possibilities for therapy. Dig Dis. 2014; 32 (4): 475-483.
208. Braat H, Rottiers P, Hommes D, et al. Phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin Gastroenterol Hepatol. 2006; 4 (6): 754-759.
209. Bermúdez-Humarán LG, Motta JP, Aubry C, et al. Serine protease inhibitors protect better than IL-10 and TGF-β anti-inflammatory cytokines against mouse colitis when delivered by recombinant lactococci. Microbial Cell Factories. 2015; 14: 26.
210. Felice C, Lewis A, Armuzzi A, Lindsay JO, Silver A,. Review article: selective histone deacetylase isoforms as potential therapeutic targets in inflammatory bowel diseases. Aliment Pharmacol Ther. 2015; 41 (1): 26-38.
211. de Zoeten EF, Wang L, Sai H,. Inhibition of HDAC9 increases T regulatory cell function and prevents colitis in mice. Gastroenterology. 2010; 138: 583-594.
212. D'Haens GR, Geboes K, Peeters M, Baert F, Penninckx F, Rutgeerts P,. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology. 1998; 114: 262-267.
213. Kovács M, Müller KE, Papp M, Lakatos PL, Csöndes M, Veres G,. New serological markers in pediatric patients with inflammatory bowel disease. World J Gastroenterol. 2014; 20 (17): 4873-4882.
214. Seow CH, Stempak JM, Xu W, et al. Novel anti-glycan antibodies related to inflammatory bowel disease diagnosis and phenotype. Am J Gastroenterol. 2009; 104 (6): 1426-1434.
215. Dubinsky MC, Kugathasan S, Mei L, et al. Increased immune reactivity predicts aggressive complicating Crohn's disease in children. Clin Gastroenterol Hepatol. 2008; 6: 1105-1111.
216. Markowitz J, Kugathasan S, Dubinsky M, et al. Age of diagnosis influences serologic responses in children with Crohn's disease: a possible clue to etiology? Inflamm Bowel Dis. 2009; 15: 714-719.
217. Kevans D, Waterman M, Milgrom R, Xu W, Van Assche G, Silverberg M,. Serological markers associated with disease behavior and response to anti-TNF therapy in ulcerative colitis. J Gastroenterol Hepatol. 2015; 30 (1): 64-70.
218. Sellon RK, Tonkonogy S, Schultz M, et al. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun. 1998; 66: 5224-5231.
219. Schaubeck M, Clavel T, Calasan J, et al. Dysbiotic gut microbiota causes transmissible Crohn's disease-like ileitis independent of failure in antimicrobial defence. [published online Apr 17, 2015]. Gut.